A naturalistic longitudinal study of at-risk mental state with a 2.4 year follow-up at a specialized clinic setting in Japan

Schizophrenia Research

Volumn 158, Issue 1-3, 2014, Pages 32-38

  Katsura, Masahiro ^a   Ohmuro, Noriyuki ^a   Obara, Chika ^b   Kikuchi, Tatsuo ^b   Ito, Fumiaki ^b,c   Miyakoshi, Tetsuo ^d   Matsuoka, Hiroo ^a,b   Matsumoto, Kazunori ^a,b  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Tohoku Medical and Pharmaceutical University Hospital   (Japan)

^d Chiba Prison   (Japan)

Author keywords

Antipsychotics; Clinical high risk; Early intervention; Psychosis; Schizophrenia; Ultra high risk (UHR)

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; AT RISK MENTAL STATE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EMOTIONAL DISORDER; FEMALE; FOLLOW UP; HUMAN; INTENSIVE CARE; JAPAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MENTAL HEALTH; OUTCOME ASSESSMENT; PATIENT REFERRAL; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PSYCHOSIS; RISK ASSESSMENT; RISK REDUCTION; THOUGHT DISORDER; DISEASE COURSE; KAPLAN MEIER METHOD; PRODROMAL SYMPTOM; PSYCHOLOGY; PSYCHOTIC DISORDERS; RISK; YOUNG ADULT;

DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; MALE; PRODROMAL SYMPTOMS; PSYCHOTIC DISORDERS; RISK; YOUNG ADULT;

EID: 84906938499     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.06.013     Document Type: Article

References (48)

1. Addington D., Addington J., Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br. J. Psychiatry 1993, 22(12):39-44.
2. Addington J., Cadenhead K.S., Cannon T.D., Cornblatt B., McGlashan T.H., Perkins D.O., Seidman L.J., Tsuang M., Walker E.F., Woods S.W., Heinssen R., North American Prodrome Longitudinal S. North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr. Bull. 2007, 33(3):665-672.
3. Addington J., Marshall C., French P. Cognitive behavioral therapy in prodromal psychosis. Curr. Pharm. Des. 2012, 18(4):558-565.
4. Amminger G.P., Schafer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. Gen. Psychiatry 2010, 67(2):146-154.
5. Beck A.T. Cognitive Therapy and the Emotional Disorders 1976, International Universities Press, New York.
6. Beck A., Steer R., Brown G. Beck Depression Inventory-II (BDI-II) 1996, The Psychological Corporation, San Antonio, TX.
7. Burns J.K. Pathways from cannabis to psychosis: a review of the evidence. Front. Psychiatry 2013, 4(10):128.
8. Cannon T.D., Cadenhead K., Cornblatt B., Woods S.W., Addington J., Walker E., Seidman L.J., Perkins D., Tsuang M., McGlashan T., Heinssen R. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry 2008, 65(1):28-37.
9. Cornblatt B.A., Auther A.M., Niendam T., Smith C.W., Zinberg J., Bearden C.E., Cannon T.D. Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr. Bull. 2007, 33(3):688-702.
10. Demjaha A., Valmaggia L., Stahl D., Byrne M., McGuire P. Disorganization/cognitive and negative symptom dimensions in the at-risk mental state predict subsequent transition to psychosis. Schizophr. Bull. 2012, 38(2):351-359.
11. French P., Morrison A.P. Early Detection and Cognitive Therapy for People at High Risk of Developing Psychosis: A Treatment Approach 2004, John Wiley & Sons, London.
12. Fujisawa D., Hashimoto N., Koizumi Y., Otsuka K., Okugawa G. Multi-center collaborative study on pathway to psychiatric care: a pilot study in Japan. Clin. Psychiatry 2007, 49(1):7-15.
13. Fusar-Poli P., Bonoldi I., Yung A.R., Borgwardt S., Kempton M.J., Valmaggia L., Barale F., Caverzasi E., McGuire P. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch. Gen. Psychiatry 2012, 69(3):220.
14. Fusar-Poli P., Borgwardt S., Bechdolf A., Addington J., Riecher-Rossler A., Schultze-Lutter F., Keshavan M., Wood S., Ruhrmann S., Seidman L.J., Valmaggia L., Cannon T., Velthorst E., De Haan L., Cornblatt B., Bonoldi I., Birchwood M., McGlashan T., Carpenter W., McGorry P., Klosterkötter J., McGuire P., Yung A. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 2013, 70(1):107-120.
15. Fusar-Poli P., Byrne M., Badger S., Valmaggia L., McGuire P. Outreach and support in South London (OASIS), 2001-2011: ten years of early diagnosis and treatment for young individuals at high clinical risk for psychosis. Eur. Psychiatry 2013, 28(5):315-326.
16. Fusar-Poli P., Nelson B., Valmaggia L., Yung A.R., McGuire P.K. Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. Schizophr. Bull. 2014, 40(1):120-131.
17. Hagi N., Takamura M., Yokoyama K. Factors affecting early psychiatric intervention for patients with first-episode psychosis in Japan. Early Interv. Psychiatry 2013, 7(3):255-260.
18. Hall R.C. Global assessment of functioning. A modified scale. Psychosomatics 1995, 36(3):267-275.
19. International Early Psychosis Association Writing Group International clinical practice guidelines for early psychosis. Br. J. Psychiatry 2005, 187(48):120-124.
20. Kristensen K., Cadenhead K.S. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res. 2007, 151(1-2):151.
21. Kwon J.S., Byun M.S., Lee T.Y., An S.K. Early intervention in psychosis: insights from Korea. Asian J. Psychiatry 2012, 5(1):98-105.
22. Liu C.C., Lai M.C., Liu C.M., Chiu Y.N., Hsieh M.H., Hwang T.J., Chien Y.L., Chen W.J., Hua M.S., Hsiung P.C., Huang Y.C., Hwu H.G. Follow-up of subjects with suspected pre-psychotic state in Taiwan. Schizophr. Res. 2011, 126(1-3):65-70.
23. McGlashan T.H., Zipursky R.B., Perkins D., Addington J., Miller T., Woods S.W., Hawkins K.A., Hoffman R.E., Preda A., Epstein I., Addington D., Lindborg S., Trzaskoma Q., Tohen M., Breier A. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatry 2006, 163(5):790-799.
24. McGorry P.D., Yung A.R., Phillips L.J., Yuen H.P., Francey S., Cosgrave E.M., Germano D., Bravin J., McDonald T., Blair A., Adlard S., Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry 2002, 59(10):921-928.
25. Miyakoshi T., Matsumoto K., Ito F., Ohmuro N., Matsuoka H. Application of the comprehensive assessment of at-risk mental states (CAARMS) to the Japanese population: reliability and validity of the Japanese version of the CAARMS. Early Interv. Psychiatry 2009, 3(2):123-130.
26. Mizuno M., Nemoto T., Tsujino N., Funatogawa T., Takeshi K. Early psychosis in Asia: insights from Japan. Asian J. Psychiatry 2012, 5(1):93-97.
27. Morita K., Kobayashi H., Takeshi K., Tsujino N., Nemoto T., Mizuno M. Poor outcome associated with symptomatic deterioration among help-seeking individuals at risk for psychosis: a naturalistic follow-up study. Early Interv. Psychiatry 2014, 8(1):24-31.
28. Nelson B., Yuen H.P., Wood S.J., Lin A., Spiliotacopoulos D., Bruxner A., Broussard C., Simmons M., Foley D.L., Brewer W.J. Long-term follow-up of a group at ultra high risk ("prodromal") for psychosis the PACE 400 study. JAMA Psychiatry 2013, 70(8):793-802.
29. Phillips L.J., Curry C., Yung A.R., Yuen H.P., Adlard S., McGorry P.D. Cannabis use is not associated with the development of psychosis in an 'ultra' high-risk group. Aust. N. Z. J. Psychiatry 2002, 36(6):800-806.
30. Phillips L., Addington J., Morrison A. At-risk mental state: management. The Recognition and Management of Early Psychosis: A Preventive Approach 2009, Cambridge University Press, New York. second ed. H. Jackson, P. McGorry (Eds.).
31. Preti A., Cella M. Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr. Res. 2010, 123(1):30-36.
32. Rapp C., Bugra H., Riecher-Rossler A., Tamagni C., Borgwardt S. Effects of cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post mortem studies. Curr. Pharm. Des. 2012, 18(32):5070-5080.
33. Ruhrmann S., Schultze-Lutter F., Salokangas R.K., Heinimaa M., Linszen D., Dingemans P., Birchwood M., Patterson P., Juckel G., Heinz A., Morrison A., Lewis S., von Reventlow H.G., Klosterkötter J. Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch. Gen. Psychiatry 2010, 67(3):241-251.
34. Schultze-Lutter F., Klosterkötter J., Picker H., Steinmeyer E.M., Ruhrmann S. Predicting first-episode psychosis by basic symptom criteria. Clin. Neuropsychiatry 2007, 4(1):11-22.
35. Stafford M.R., Jackson H., Mayo-Wilson E., Morrison A.P., Kendall T. Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 2013, 346:f185.
36. Stowkowy J., Colijn M.A., Addington J. Pathways to care for those at clinical high risk of developing psychosis. Early Interv. Psychiatry 2013, 7(1):80-83.
37. Tsuang M.T., Van Os J., Tandon R., Barch D.M., Bustillo J., Gaebel W., Gur R.E., Heckers S., Malaspina D., Owen M.J., Schultz S., Carpenter W. Attenuated psychosis syndrome in DSM-5. Schizophr. Res. 2013, 150(1):31-35.
38. Valmaggia L.R., Stahl D., Yung A.R., Nelson B., Fusar-Poli P., McGorry P.D., McGuire P.K. Negative psychotic symptoms and impaired role functioning predict transition outcomes in the at-risk mental state: a latent class cluster analysis study. Psychol. Med. 2013, 43(11):2311-2325.
39. van der Gaag M., Smit F., Bechdolf A., French P., Linszen D.H., Yung A.R., McGorry P., Cuijpers P. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12month and longer-term follow-ups. Schizophr. Res. 2013, 149(1-3):56-62.
40. Velthorst E., Nieman D.H., Becker H.E., van de Fliert R., Dingemans P.M., Klaassen R., de Haan L., van Amelsvoort T., Linszen D.H. Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis. Schizophr. Res. 2009, 109(1-3):60-65.
41. Walker E.F., Cornblatt B.A., Addington J., Cadenhead K.S., Cannon T.D., McGlashan T.H., Perkins D.O., Seidman L.J., Tsuang M.T., Woods S.W., Heinssen R. The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample. Schizophr. Res. 2009, 115(1):50-57.
42. Woods S.W., Walsh B.C., Saksa J.R., McGlashan T.H. The case for including attenuated psychotic symptoms syndrome in DSM-5 as a psychosis risk syndrome. Schizophr. Res. 2010, 123(2-3):199-207.
43. Yung A.R., McGorry P.D., McFarlane C.A., Jackson H.J., Patton G.C., Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophr. Bull. 1996, 22(2):283-303.
44. Yung A.R., Phillips L.J., Yuen H.P., Francey S.M., McFarlane C.A., Hallgren M., McGorry P.D. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr. Res. 2003, 60(1):21-32.
45. Yung A.R., Yuen H.P., McGorry P.D., Phillips L.J., Kelly D., Dell'Olio M., Francey S.M., Cosgrave E.M., Killackey E., Stanford C., Godfrey K., Buckby J. Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states. Aust. N. Z. J. Psychiatry 2005, 39(11-12):964-971.
46. Yung A.R., Stanford C., Cosgrave E., Killackey E., Phillips L., Nelson B., McGorry P.D. Testing the ultra high risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr. Res. 2006, 84(1):57-66.
47. Yung A.R., Nelson B., Thompson A.D., Wood S.J. Should a "risk syndrome for psychosis" be included in the DSMV?. Schizophr. Res. 2010, 120(1-3):7-15.
48. Ziermans T.B., Schothorst P.F., Sprong M., van Engeland H. Transition and remission in adolescents at ultra-high risk for psychosis. Schizophr. Res. 2011, 126(1-3):58-64.